The U.S. Food and Drug Administration (FDA) is still reviewing Intercept Pharmaceuticals’ application for full approval of Ocaliva (obeticholic acid) as a second-line…
News
CHOLESTASIS
NewsExcessive copper in PFIC3 may lead to misdiagnosis: Case report
Excessive copper levels in the body led to an initial misdiagnosis of Wilson disease, a rare condition marked by copper buildup in the liver and…
FATTY LIVER DISEASE
NewsTherapy to silence SPTBN1 protein eases liver fat, scarring in mice
Suppressing the production of the SPTBN1 protein reduces liver fat, inflammation, and scarring (fibrosis) in mouse and human models of two forms of fatty…
ALAGILLE SYNDROME
NewsNew study may explain milder liver scarring seen in Alagille syndrome
Alterations to the immune system may underlie the mild liver scarring, or fibrosis, that characterizes Alagille syndrome despite severe liver disease, according to a…
Fewer than half of reproductive-aged women with opioid use disorder in the U.S. undergo hepatitis C testing, with Black and Asian women less likely…
CHOLANGITIS
NewsFDA names volixibat, for itching due to PBC, a breakthrough therapy
The U.S. Food and Drug Administration (FDA) has designated Mirum Pharmaceuticals’ oral candidate volixibat a breakthrough therapy for the treatment of itching, or…
CHOLESTASIS
NewsNew ABCB11 mutation linked to PFIC2, hypothyroidism in boy
A new ABCB11 gene mutation was the likely cause of progressive familial intrahepatic cholestasis type 2 (PFIC2) in a boy who was also born with…
FATTY LIVER DISEASE
NewsSurvodutide wins breakthrough therapy for fatty liver disease
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy status to survodutide, an experimental injectable therapy by Boehringer Ingelheim for metabolic dysfunction-associated steatohepatitis…
BILIARY ATRESIA
NewsAmerican Liver Foundation launches free toolkit for children
The American Liver Foundation (ALF) has launched a toolkit — featuring a plush lion named Bili the Brave — to support children and families…
HEPATITIS
NewsAbbvie pulls 2 hepatitis treatments from EU market
Abbvie has decided to permanently discontinue the marketing of antiviral treatments Exviera (dasabuvir) and Viekirax (ombitasvir/paritaprevir/ritonavir) for adults with chronic hepatitis…
Recent Posts
- World Liver Day promotes small habits that can yield big health gains
- FDA puts pevifoscorvir sodium for hepatitis B on fast track
- Off-label fenofibrate improves liver health in PBC patients: Study
- Gestational diabetes boosts risk of liver issue during pregnancy: Study
- Learning how to let go of worry isn’t easy as an Alagille parent